Tamoxifen is an anti-oestrogen commonly used in the treatment of breast cancer. It also has some oestrogenic properties and this may lead to endometrial cancer.

The levonorgestrel IUS (Mirena)  reduces endometrial activity. It is theoretically possible that it could reduce endometrial pathology resulting from tamoxifen. The early results of a study have shown that it reduces the incidence of endometrial polyps at 12 months.

Related Medical Abstracts - Click on the paper title:-

Please click on the required question.

Women's Health